Amgen 2004 Annual Report Download - page 31

Download and view the complete annual report

Please find page 31 of the 2004 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 38

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38

(4) In November 2004, we issued $1.0 billion aggregate principal amount of 4.00% senior notes due 2009 and $1.0 billion aggregate principal amount of 4.85% senior notes due 2014.
In March 2002, we issued zero-coupon, senior convertible notes (the “Convertible Notes”) with a face amount at maturity of $3.95 billion. The holders of the Convertible Notes may require
us to purchase all or a portion of their notes on various dates, the earliest of which is March 1,2005. On March 2,2005, as a result of certain holders of the Convertible Notes exercising
their March 1,2005 put option, we repurchased $1,175 million, or approximately 40%, of the outstanding Convertible Notes at their then-accreted value for cash. Concurrently, we amended
the terms of the Convertible Notes to add an additional put date in order to permit the remaining holders, at their option, to cause us to repurchase the Convertible Notes on March 1,2006
at the then-accreted value. Accordingly, the portion of the Convertible Notes outstanding at December 31,2004 not repurchased on March 2,2005 was classifi ed as long-term debt. See Note 4
to the Consolidated Financial Statements included in our 2004 Annual Report on Form 10-K for further discussion of the terms of the Convertible Notes.
2001 2000 1999 1998 1997 1996 1995
$3,511 $3,202 $3,043 $2,514 $2,220 $2,088 $1,819
505 427 297 204 181 152 121
4,016 3,629 3,340 2,718 2,401 2,240 1,940
443 408 402 345 301 283 273
865 845 823 663 631 528 452
—
30
—————
974 851 671 544 520 523 472
—— —————
203 (49) (49) (23) 157
——
1,120 1,139 1,096 863 644 680 538
1.03 1.05 1.02 0.82 0.59 0.61 0.48
2001 2000 1999 1998 1997 1996 1995
$6,443 $5,400 $4,078 $3,672 $3,110 $2,766 $2,433
223 223 223 223 229 59 177
5,217 4,315 3,024 2,562 2,139 1,906 1,672
95 96 97 98 99 00 01 02 03 04
2004 $10,550
2003 8,356
2002 5,523
2001 4,016
2000 3,629
1999 3,340
1998 2,718
1997 2,401
1996 2,240
1995 1,940
Total revenues
($ in millions )
2004 $1,900
2003 1,300
2002 362
02 03 04
ENBREL®(1)
product sales
($ in millions )
95 96 97 98 99 00 01 02 03 04
2004 $9,977
2003 7,868
2002 4,991
2001 3,511
2000 3,202
1999 3,043
1998 2,514
1997 2,220
1996 2,088
1995 1,819
Total product sales
($ in millions )
Amgen 2004 Annual Report page 29